FindTrial
Sign In

TEW-7197

DRUG7 trials

Sponsors

MedPacto, Inc., Joon Oh Park

Conditions

Advanced Stage Solid TumorsGastric CancerGastroesophageal Junction AdenocarcinomaHealthy VolunteersMetastatic Colorectal CancerMetastatic Gastric CancerMetastatic Pancreatic CancerMyelodysplastic Syndromes

Phase 1

First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
CompletedNCT02160106
MedPacto, Inc.Advanced Stage Solid Tumors
Start: 2014-07-29End: 2018-08-28Updated: 2019-05-09
Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
CompletedNCT03074006
MedPacto, Inc.Myelodysplastic Syndromes
Start: 2018-01-04End: 2019-12-31Updated: 2021-09-28
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel
NCT03666832
Joon Oh ParkMetastatic Pancreatic Cancer
Start: 2019-06-17End: 2023-12-30Target: 36Updated: 2022-06-15
TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer
CompletedNCT03698825
MedPacto, Inc.Metastatic Gastric Cancer
Start: 2018-08-15End: 2022-12-28Updated: 2024-12-09
Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects
CompletedNCT03704675
MedPacto, Inc.Healthy Volunteers
Start: 2018-08-08End: 2018-10-20Updated: 2020-04-14
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
CompletedNCT03724851
MedPacto, Inc.Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer
Start: 2018-12-20End: 2024-05-07Updated: 2025-03-25
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
CompletedNCT03732274
MedPacto, Inc.Non-Small Cell Lung Cancer Metastatic
Start: 2019-02-11End: 2024-05-17Updated: 2025-04-10

Related Papers

Vactosertib plus pembrolizumab in patients with non-microsatellite instability-high metastatic colorectal or gastric cancer: a multicenter, phase Ib/IIa study.
2026-07-21
New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
Abstract A017: Phase 1b Study of 2nd line vactosertib plus oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed first-line gemcitabine with nab-paclitaxel
Cancer Research2022-11-15
Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/<i>nab</i>-paclitaxel.
Journal of Clinical Oncology2022-06-016 citations
74 Tumor microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the response of MSS mCRC patients treated vactosertib in combination with pembrolizumab
Regular and Young Investigator Award Abstracts2021-11-013 citations
823 Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab
Regular and Young Investigator Award Abstracts2021-11-01
Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer.
Journal of Clinical Oncology2021-05-2031 citations
363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result
Regular and Young Investigator Award Abstracts2020-11-016 citations
332 Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab
Regular and Young Investigator Award Abstracts2020-11-015 citations
Safety and preliminary antitumor activity of the transforming growth factor beta (TGF-β) receptor I kinase inhibitor, vactosertib, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma.
Journal of Clinical Oncology2020-05-208 citations
Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS
Blood2019-11-135 citations
Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
Journal of Clinical Oncology2018-05-2033 citations